Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook

Total revenues in the first quarter were $44.0 billion, and adjusted revenues¹ were $44.1 billion
Shareholders' net income for the first quarter was $1.2 billion, or $3.68 per share
Adjusted income from operations² for the first quarter was $1.9 billion, or $6.01 per share
Adjusted income from operations^2,3 for 2022 is now projected to be at least $22.60 per share³

BLOOMFIELD, Conn., May 6, 2022 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE: CI) today reported strong first quarter 2022 results reflecting revenue and earnings growth across its businesses.

"We've had a strong start to the year as we advance our growth strategy and support the health and well-being of our clients and customers," said David M. Cordani, chairman and chief executive officer. "We're taking decisive steps forward with innovation, new partnerships and re-investing in our company so we can achieve greater impact for the customers and communities we're privileged to serve."

Total revenues for first quarter 2022 were $44.0 billion. Adjusted revenues¹ were $44.1 billion and reflect strong contributions from each of Cigna's ongoing businesses.

Shareholders' net income for first quarter 2022 was $1.2 billion, or $3.68 per share, compared with $1.2 billion, or $3.30 per share, for first quarter 2021.

Cigna's adjusted income from operations² for first quarter 2022 was $1.9 billion, or $6.01 per share, compared with $1.7 billion, or $4.73 per share, for first quarter 2021 reflecting strong earnings contributions across the Company's businesses.

Reconciliations of total revenues to adjusted revenues¹ and of shareholders' net income to adjusted income from operations² are provided on the following page and on Exhibit 1 of this earnings release.

CONSOLIDATED HIGHLIGHTS

The following table includes highlights of results and reconciliations of total revenues to adjusted revenues¹ and shareholders' net income to adjusted income from operations²:

Consolidated Financial Results (dollars in millions):
	Three Months Ended
	March 31,		December 31,
	2022	2021	2021

Total Revenues	$ 44,005	$ 40,971	$ 45,688
Net Realized Investment (Gains) Losses from Equity Method Investments¹	103	14	(12)
Adjusted Revenues¹	$ 44,108	$ 40,985	$ 45,676

Consolidated Earnings, net of taxes
Shareholders' Net Income	$ 1,183	$ 1,161	$ 1,116
Net Realized Investment (Gains) Losses²	355	13	(59)
Amortization of Acquired Intangible Assets²	356	388	326
Special Items²	37	102	189
Adjusted Income from Operations²	$ 1,931	$ 1,664	$ 1,572

Shareholders' Net Income, per share	$ 3.68	$ 3.30	$ 3.39
Adjusted Income from Operations², per share	$ 6.01	$ 4.73	$ 4.77

Year to date through May 5, 2022, the Company repurchased 7.6 million shares of common stock for approximately $1.8 billion.
The debt-to-capitalization ratio was 41.9% at March 31, 2022, in line with fourth quarter 2021.
The adjusted SG&A expense ratio⁴ was 7.4% for first quarter 2022 compared to 8.0% for first quarter 2021, driven by revenue growth and continued expense efficiency.

CUSTOMER RELATIONSHIPS

The following table summarizes Cigna's medical customers and overall customer relationships:

Customer Relationships (in thousands):
	As of the Periods Ended
	March 31,		December 31,
	2022	2021	2021

Total Customer Relationships⁵	190,370	177,607	185,672

Total Pharmacy Customers	107,440	101,002	107,298

U.S. Commercial	14,621	13,552	13,854
U.S. Government	1,402	1,464	1,510
International Health	1,756	1,655	1,717
Total Medical Customers^5,6	17,779	16,671	17,081

Behavioral Care	44,078	38,950	40,380
Dental	18,169	17,800	17,731
Medicare Part D	2,904	3,184	3,182

Total customer relationships⁵ at first quarter 2022 grew by 3% year to date to 190.4 million.
The total medical customer base^5,6 at first quarter 2022 grew to 17.8 million, an increase of 698,000 customers year to date, driven by growth in U.S. Commercial fee-based client relationships, partially offset by a decrease in U.S. Government inclusive of the divestiture of the Medicaid business.

HIGHLIGHTS OF SEGMENT RESULTS

See Exhibit 1 for a reconciliation of adjusted income (loss) from operations² to shareholders' net income.

Evernorth

This segment includes a broad range of coordinated and point solution health services and capabilities, including pharmacy solutions, benefits management solutions, care delivery and care management solutions, and intelligence solutions, which are provided to health plans, employers, government organizations, and health care providers.

Financial Results (dollars in millions):
	Three Months Ended
	March 31,		December 31,
	2022	2021	2021

Adjusted Revenues¹	$ 33,586	$ 30,620	$ 35,086
Adjusted Income from Operations, Pre-Tax²	$ 1,302	$ 1,223	$ 1,634
Adjusted Margin, Pre-Tax⁷	3.9%	4.0%	4.7%

First quarter 2022 adjusted revenues¹ increased 10% relative to first quarter 2021 reflecting strong organic growth in specialty pharmacy services.
First quarter 2022 adjusted income from operations, pre-tax² increased 6% relative to first quarter 2021, reflecting continued affordability improvements and business growth, partially offset by strategic investments in expanding our services portfolio and digital capabilities.

Cigna Healthcare⁶

This segment includes Cigna's U.S. Commercial, U.S. Government, and International Health businesses that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. U.S. Government solutions include Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, and individual health insurance plans both on and off the public exchanges. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

Financial Results (dollars in millions):
	Three Months Ended
	March 31,		December 31,
	2022	2021	2021

Adjusted Revenues^1,8	$ 11,392	$ 11,067	$ 11,214
Adjusted Income from Operations, Pre-Tax²	$ 1,279	$ 1,042	$ 472
Adjusted Margin, Pre-Tax⁷	11.2%	9.4%	4.2%

First quarter 2022 adjusted revenues^1,8 grew 3% over first quarter 2021, reflecting increased specialty contributions and premium increases to cover underlying cost trends, partially offset by the divestiture of the Medicaid business.
First quarter 2022 adjusted income from operations, pre-tax² and adjusted margin, pre-tax⁷ increased relative to first quarter 2021 primarily due to increased specialty contributions.
The Cigna Healthcare MCR⁴ of 81.5% for first quarter 2022 compares to 80.9% for first quarter 2021, reflecting risk adjustment updates related to prior years and higher medical costs in the Individual business, partially offset by lower direct COVID-19 costs.
Cigna Healthcare net medical costs payable⁹ was $4.29 billion at March 31, 2022, $3.79 billion at March 31, 2021, and $4.00 billion at December 31, 2021. Favorable prior year reserve development on a gross pre-tax basis was $276 million and $233 million through first quarter 2022 and 2021, respectively.

Corporate and Other Operations⁶

Corporate reflects interest expense, as well as amounts not allocated to operating segments and includes intersegment eliminations. Additionally, this discussion includes items reported in Other Operations which is comprised of the international life, accident, and supplemental benefits businesses held for sale pending divestiture⁶, Corporate Owned Life Insurance ("COLI"), our interest in a joint venture in Turkey and the Company's run-off operations.

Financial Results (dollars in millions):
	Three Months Ended
	March 31,		December 31,
	2022	2021	2021

Adjusted (Loss) from Operations, Pre-Tax²	$ (117)	$ (123)	$ (115)

First quarter 2022 adjusted loss from operations, pre-tax² was favorable to first quarter 2021 primarily reflecting lower interest expense.

2022 OUTLOOK

Cigna's outlook for full year 2022 adjusted revenues^1,3 is projected to be at least $177 billion. Cigna's outlook for full year 2022 consolidated adjusted income from operations^2,3 is projected to be at least $7.05 billion, or at least $22.60 per share³. Additionally, this outlook includes the impact of expected future share repurchases, anticipated 2022 dividends, and assumes that the previously announced divestiture of our international life, accident, and supplemental benefits businesses⁶ will close in the second quarter of 2022.

(dollars in millions, except where noted and per share amounts)
2022 Consolidated Metrics	Projection for Full Year Ending December 31, 2022	Change from Prior Projection
Adjusted Revenues^1,3	at least $177,000
Adjusted Income from Operations^2,3	at least $7,050	+$100
Adjusted Income from Operations, per share^2,3	at least $22.60	+$0.20
Adjusted SG&A Expense Ratio^3,4	6.9% to 7.3%
Adjusted Tax Rate^3,10	22.0% to 22.5%
Cash Flow from Operations³	at least $8,250
Weighted Average Shares Outstanding (millions)³	310 to 314	+2.0 at the midpoint

2022 Evernorth Metrics
Adjusted Income from Operations, Pre-Tax^2,3	~$6,100

2022 Cigna Healthcare Metrics
Adjusted Income from Operations, Pre-Tax^2,3	~$3,950	+$50
Medical Care Ratio^3,4	82.0% to 83.5%
Total Medical Customer Growth (lives)^3,5	at least 725,000	+150,000

The foregoing statements represent the Company's current estimates of Cigna's 2022 consolidated and segment adjusted income from operations^2,3 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

This quarterly earnings release and the Quarterly Financial Supplement are available on Cigna's website in the Investor Relations section (https://investors.cigna.com/home/default.aspx). Management will be hosting a conference call to review first quarter 2022 results and discuss full year 2022 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of Cigna's website located at https://investors.cigna.com/events-and-presentations/default.aspx.

The call-in numbers for the conference call are as follows:

Live Call
(888) 455-5036 (Domestic)
(773) 799-3981 (International)
Passcode: 562022

Replay
(866) 357-1405 (Domestic)
(203) 369-0111 (International)

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

About Cigna

Cigna Corporation (NYSE: CI) is a global health services company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth companies or their affiliates, and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products.

Cigna maintains sales capability in over 30 countries and jurisdictions, and has over 190 million customer relationships throughout the world. To learn more about Cigna^®, including links to follow us on Facebook or Twitter, visit www.cigna.com.

Notes:
1.	Adjusted revenues is used by Cigna's management because it permits analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues.

2.	Adjusted income (loss) from operations is a principal financial measure of profitability used by Cigna's management because it presents the underlying results of operations of Cigna's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income from operations is defined as shareholders' net income (or income before income taxes less pre-tax income/loss attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

3.	Management is not able to provide a reconciliation of adjusted income from operations to shareholders' net income (loss) or adjusted revenues to total revenues on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond Cigna's control. As such, any associated estimate and its impact on shareholders' net income and total revenues could vary materially.

	The Company's outlook assumes that the previously announced divestiture of the international life, accident, and supplemental benefits businesses⁶will close in the second quarter of 2022 but excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company's outlook includes the potential effects of expected future share repurchases and anticipated 2022 dividends.

	As announced in January 2021, Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

	The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

4.	Operating ratios are defined as follows:
	•	The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all U.S. Commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products provided through guaranteed cost or experience-rated funding arrangements, as well as Medicare Advantage, Medicare Part D, Medicare Supplement, individual on and off-exchange products, and health care products within our International Health business, within the Cigna Healthcare segment.
	•	Adjusted SG&A expense ratio represents enterprise selling, general and administrative expenses excluding special items as a percentage of adjusted revenue at a consolidated level.

5.	Customer relationships are defined as follows:
	•	Total medical customers includes individuals in the Cigna Healthcare segment who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna; have access to Cigna's provider network for covered services under their medical plan; or have medical claims and services that are administered by Cigna.
	•	Prior year lives include the Medicaid customers which was divested on January 1, 2022.
	•	International Health medical customers excludes medical customers served by less than 100% owned subsidiaries and customers that are part of the businesses to be sold pursuant to the previously announced divestiture of the international life, accident, and supplemental benefits businesses⁶. Prior year lives have been restated to conform to this presentation.
	•	Policies issued by the businesses subject to the definitive agreement to sell certain of our international life, accident, and supplemental benefits businesses⁶ and our joint venture in Turkey have been excluded from customer relationships.

6.	We entered into a definitive agreement in October 2021 to sell our life, accident, and supplemental benefits businesses in several countries to Chubb INA Holdings, Inc. ("Chubb"). As of March 31, 2022 we now expect to sell our life, accident, and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for $5.72 billion in cash (the "Chubb Transaction"); we no longer expect to sell our interest in a joint venture in Turkey as part of the Chubb Transaction. Subject to applicable regulatory approvals and customary closing conditions, we expect to complete this transaction in the second quarter of 2022.

	In connection with the pending Chubb Transaction, we revised our business reporting structure. As such we adjusted our segment reporting effective in the fourth quarter of 2021 and segment results for the three months ended March 31, 2021 have been restated to conform to the new segment presentation. See Cigna's Current Report on Form 8-K filed on January 24, 2022 for additional information.

7.	Adjusted margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

8.	Cigna owns a 50% noncontrolling interest in its China joint venture. As such, the adjusted revenues for the Cigna Healthcare segment only include Cigna's 50% share of the joint venture's earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.

9.	Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $4.49 billion as of March 31, 2022, $4.26 billion as of December 31, 2021, and $4.03 billion as of March 31, 2021.

10.	The measure "adjusted tax rate" is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, "consolidated effective tax rate". We define adjusted tax rate as the consolidated income tax rate applicable to the Company's pre-tax income excluding pre-tax income/loss attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof include (i) future net realized investment results and (ii) future special items.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2022 on a consolidated, per share, and segment basis; projected adjusted revenue outlook for 2022; projected total medical customer growth over year end 2021; projected medical care and adjusted SG&A expense ratios; projected consolidated adjusted tax rate; projected cash flow from operations; future dividends; projected weighted average shares outstanding; future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients, including in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of the developing inflationary pressures; the ongoing Russia-Ukraine conflict; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions, including the sale of our international life, accident and supplemental benefits businesses; and other statements regarding Cigna's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; the scale, scope and duration of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows or financial condition; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations; risks related to strategic transactions and realization of the expected benefits of such transactions, including with respect to the sale of our international life, accident and supplemental benefits businesses, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, stock market or interest rate declines and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; unfavorable industry, economic or political conditions; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-K, 10-Q and 8-K available through the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

CIGNA CORPORATION			Exhibit 1
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
(Dollars in millions, except per share amounts)
	Three Months Ended		Three Months Ended
	March 31,		December 31,
	2022	2021	2021

REVENUES

Pharmacy revenues	$ 30,697	$ 28,025	$ 32,328
Premiums	10,356	10,214	10,342
Fees and other revenues	2,538	2,341	2,638
Net investment income	414	391	380
Total Revenues	44,005	40,971	45,688
Net realized investment results from certain equity method investments	103	14	(12)
Adjusted revenues⁽¹⁾	$ 44,108	$ 40,985	$ 45,676

SHAREHOLDERS' NET INCOME

Shareholders' net income	$ 1,183	$ 1,161	$ 1,116
After-tax adjustments to reconcile adjusted income from operations
Net realized investment (gains) losses ⁽²⁾	355	13	(59)
Amortization of acquired intangible assets	356	388	326
Special Items
Integration and transaction-related costs	37	22	70
Debt extinguishment costs	—	101	—
(Benefits) charges associated with litigation matters	—	(21)	—
Charge for organizational efficiency plan	—	—	119
Adjusted income from operations	$ 1,931	$ 1,664	$ 1,572

Pre-tax adjusted income (loss) from operations by segment
Evernorth	$ 1,302	$ 1,223	$ 1,634
Cigna Healthcare	1,279	1,042	472
Corporate and Other Operations	(117)	(123)	(115)
Consolidated pre-tax adjusted income from operations	2,464	2,142	1,991
Adjusted income tax expense	(533)	(478)	(419)
Consolidated after-tax adjusted income from operations	$ 1,931	$ 1,664	$ 1,572

DILUTED EARNINGS PER SHARE

Shareholders' net income	$ 3.68	$ 3.30	$ 3.39
After-tax adjustments to reconcile to adjusted income from operations
Net realized investment (gains) losses ⁽²⁾	1.10	0.04	(0.18)
Amortization of acquired intangible assets	1.11	1.10	0.99
Special items
Integration and transaction-related costs	0.12	0.06	0.21
Debt extinguishment costs	—	0.29	—
(Benefits) charges associated with litigation matters	—	(0.06)	—
Charge for organizational efficiency plan	—	—	0.36
Adjusted income from operations ⁽³⁾	$ 6.01	$ 4.73	$ 4.77
Weighted average shares (in thousands)	321,282	351,976	329,641
Common shares outstanding (in thousands)	318,502	344,454	322,948

SHAREHOLDERS' EQUITY at March 31,	$ 46,087	$ 48,149

SHAREHOLDERS' EQUITY PER SHARE at March 31,	$ 144.70	$ 139.78

(1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses.

(2) Includes the Company's share of certain realized investments results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.

(3) Adjusted income (loss) from operations is defined as shareholders' net income (or income before income taxes less pre-tax income/loss attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net realized investment results, amortization of acquired intangible assets and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cigna-reports-strong-first-quarter-2022-results-raises-2022-outlook-301541376.html